Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:epidermal_growth_factor
|
| gptkbp:administeredBy |
gptkb:physician
|
| gptkbp:approvedBy |
gptkb:Cuba
|
| gptkbp:clinicalTrialPhase |
gptkb:Cuba
gptkb:Russia gptkb:Turkey |
| gptkbp:compatibleWith |
gptkb:European_Union
gptkb:United_States |
| gptkbp:developedBy |
gptkb:Cuba
gptkb:Center_for_Genetic_Engineering_and_Biotechnology |
| https://www.w3.org/2000/01/rdf-schema#label |
Heberprot-P
|
| gptkbp:marketedIn |
gptkb:Cuba
several countries in Latin America |
| gptkbp:patent |
gptkb:Cuba
|
| gptkbp:reduces |
risk of amputation in diabetic foot ulcer patients
|
| gptkbp:routeOfAdministration |
injection
|
| gptkbp:sideEffect |
allergic reaction
pain at injection site local infection |
| gptkbp:usedFor |
treatment of diabetic foot ulcers
|
| gptkbp:bfsParent |
gptkb:CIGBS
|
| gptkbp:bfsLayer |
6
|